# Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

November 4, 2026

BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026.

**Details on the fireside chat can be found below.**

Date: Tuesday, November 10, 2026
Time: 10:00 AM EST
Webcast Link: https://event.summitcast.com/view/

Following the conclusion of the fireside chat, a replay will be available for 30 days on the "Events and Presentations" page of Larimar's website.

**About Larimar Therapeutics**
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

**Investor Contact:**
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

**Company Contact:**
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715